The addition of bevacizumab is currently recommended and has been demonstrated to be a better treatment option in chemo-naive lung adenocarcinoma patients with PD-L1–negative scores in many clinical trials and real-world studies including this study. Here, CD274 is linked to lung adenocarcinoma.